Rationale for treatment design: Biochemical modulation of 5- fluorouracil by leucovorin

Cancer Journal from Scientific American

Volumn 4, Issue 1, 1998, Pages 12-18

  Rustum, Youcef M ^a   Cao, Shousong ^a   Zhang, Zhenggang ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; LOMUSTINE; METHOTREXATE; OCTREOTIDE; THYMIDYLATE SYNTHASE; TRIMETREXATE; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; BIOTRANSFORMATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DNA SYNTHESIS INHIBITION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MOUSE; MULTICENTER STUDY; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; STOMATITIS; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG INTERACTIONS; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASMS; RATS;

EID: 0031938504     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10: 896-903.
2. Evans RM, Laskin JD, Hakala MT. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 1981;41:3288-3295.
3. Rustum YM. Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin: role of dose schedule and route of administration of leucovorin. Cancer 1989;63[suppl]:1013-1017.
4. Cao S, Frank C, Rustum YM. Role of fluoropyrimidine schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma. J Natl Cancer Inst 1996;88:430-436.
5. Keyomarsi K, Moran R. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 1986;46:5229-5235.
6. Houghton JA, Williams LG, Cheshire PJ et al. Influence of dose of [6R,S] leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts. Cancer Res 1990;50:3940-3946.
7. Houghton JA, Williams LG, de Graaf SS et al. Relationship between dose rate of [6R,S] leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res 1990;50:3493-3502.
8. Houghton JA, Williams LG, Loftin SK et al. Factors that influence the therapeutic activity of 5-fluorouracil [6R,S]leucovorin combinations in colon adenocarcinoma xenografts. Cancer Chemother Pharmacol 1992;30:423-432.
9. Mini E, Moroson BA, Bertino JR. Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin. Cancer Treatment Reports 1987;71:381-389.
10. Moran RG, Scanlon KL. Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 1991;51:4618-4623.
11. Park JG, Collins JM, Gazdar AF et al. Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst 1988;80:1560-1564.
12. Rustum YM. Modulation of fluoropyrimidines by leucovorin: rationale and status. J Surg Oncol 1991;48:116-123.
13. Zhang Z-G, Rustum YM. Effects of diastereoisomers of 5-formyltetrahydrofolate on cellular growth, sensitivity to 5-fluoro-2′-deoxyuridine, and methylenetetrahydrofolate polyglutamate levels in HCT-8 cells. Cancer Res 1991;51:3476-3481.
14. Zhang Z-G, Harstrick A, Rustum YM. Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration. Semin Oncol 1992;19[suppl 3]:10-15.
15. Drake JC, Voeller DM, Allegra CJ et al. The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells. Br J Cancer 1995;71:1145-1150.
16. Berger SH, Hakala MT. Calcium leucovorin and 5-fluorouridine cytotoxicity. JSC Med Assoc 1990;86:284-289.
17. Doroshow JH, Multhauf P, Leong L et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990;8:491-501.
18. de Gramont A, Krulik M, Cady J et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988;24:1499-1503.
19. de Gramont A, Bosset J-F, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol 1997;15:808-815.
20. Erlichman C, Fine S, Wong A et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988;6:469-475.
21. Grem JL. Fluorinated pyrimidines. In: Chabner BA, Collins JM, eds. Cancer Chemotherapy: Principles and Practice. Philadelphia: Lippincott, 1990:180-224.
22. Johnson PW, Thompson PI, Seymour MT et al. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer 1991;64:603-605.
23. Köhne CH, Hecker H, Schöffski P et al. Weekly high-dose infusional (CI) 5-FU plus folinic acid (FA) has major impact on survival in patients with advanced colorectal cancer: results of a multivariate analysis using RECPAM [abstract]. Proceedings of ASCO 1996;15:201.
24. Leichman CG, Fleming TR, Muggia FM et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995;13:1303-1311.
25. Machover D, Goldschmidt E, Chollet P et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986;4:685-696.
26. Machover D, Grison X, Goldschmidt E et al. Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. J Natl Cancer Inst 1992;84:321-327.
27. Petrelli N, Herrera L, Rustum YM et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:1559-1565.
28. Petrelli N, Douglass HO Jr, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989;7:1419-1426.
29. Petrelli N, Rustum YM. Fluorouracil and leucovorin: there is a choice [letter]. J Clin Oncol 1993;11:1434-1435.
30. Poon MA, O'Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-1418.
31. Poon MA, O'Connell MJ, Wieand HS et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967-1972.
32. Valsecchi R, Labianca R, Cascinu S et al. High-dose (HD) versus low dose (LD) L-leucovorin (LLV) as a modulator of 5-days 5-fluorouracil (5FU) in advanced colorectal cancer(ACC): a GISCAD phase III study [abstract]. Proceedings of ASCO 1995;14:195.
33. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast Powel Project protocol C-03. J Clin Oncol 1993;11:1879-1887.
34. Wolmark N, Rockette H, Mamounas EP et al. The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-LEV), and 5-FU + leucovorin + levamisole (FU-LV-LEV) in patients with Dukes B and C carcinoma of the colon: first report of NS-ABP C-04 [abstract]. Proceedings of ASCO 1996;15:205.
35. Santi DV, McHenry CS, Sommer M. Mechanism of interaction of thymidylate synthase with 5-fluorodeoxyurindylate. Biochemistry 1974;13:471-481.
36. Ullman B, Lee M, Martin JF et al. Cytotoxicity of 5-fluoro-2′-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate. Proc Natl Acad Sci U S A 1978;75:980-983.
37. Swain SM, Lippman ME, Egan EF et al. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989;7:890-899.
38. Peters GJ, van der Wilt CL, van Groeningen CJ et al. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994;12:2035-2042.
39. Peters GJ, Hoekman K, van Groeningen CJ et al. Potentiation of 5-fluorouracil induced inhibition of thymidylate synthase in human colon tumors by leucovorin is dose dependent. Adv Exp Med Biol 1993;338:613-616.
40. Buroker TR, O'Connell MJ, Wieand HS et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14-20.
41. Goldberg RM, O'Connell MJ, Wieand HS et al. A prospective randomized trial of intensive course 5-FU combined with a) the l-isomer of intravenous leucovorin, b) oral (d,l) leucovorin, or c) intravenous (d,l) leucovorin for the treatment of advanced colorectal cancer: a North Central Cancer Treatment Group trial [abstract]. Proceedings of ASCO 1996;15:207.
42. Jäger E, Heike M, Bernhard H et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. J Clin Oncol 1996;14:2274-2279.
43. Löffler TM, Weber FW, Hausamen TU. Protracted continuous-infusion 5-fluorouracil with intermittent high-dose leucovorin in advanced and metastatic colorectal cancer: a pilot study. In: Pinedo HM, Rustum YM, eds. Leucovorin Modulation of Fluoropyrimidines: A New Frontier in Cancer Chemotherapy. London: Royal Society of Medicine Services Limited, 1989:65-77.
44. Bécouarn Y, Cany L, Rouhier ML et al. High-dose folinic acid (HDFA) and 5-fluorouracil (5FU) bolus and continuous infusion in advanced colorectal cancer [abstract]. Proceedings of ASCO 1994;13:604a.
45. Beerblock K, Rinaldi Y, André T et al. Bi-weekly high-dose folinic acid (FA) and 5-fluorouracil (5FU) 48h-infusion in metastatic colorectal cancer [abstract]. Proceedings of ASCO 1996;15:490a.
46. Ardalan B, Chua L, Tian EM et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991;9:625-630.
47. Petrelli NJ, Rodriguez-Bigas M, Rustum YM et al. Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. Cancer 1993;72:1543-1546.